EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10,

Cassava Sciences (NASDAQ:SAVA) shares advanced 2.75% on Thursday after the biotech firm disclosed that the U.S. Department of Justice has formally closed its investigation into allegations of research misconduct.

Airflow Sciences Corporation has been awarded $1.15 Million from the U.S. Department of Energy to develop a specialized

The Wiley Foundation honored research into connectomes — detailed atlases of the brain that map out thousands of neurons and the millions of connection between them.

Pope Leo XIV’s recent appointee to the Pontifical Academy for Social Sciences, Tyler J. VanderWeele, is a Harvard University professor of epidemiology.

New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19,

Houston's life sciences profile was elevated by the first phase of TMC's Helix Park and Eli Lilly's $6.5B biomanufacturing investment.

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to EY’s annual Firepower Report. After a tentative 2024 ...

Students, young professionals, and industry leaders invited to explore emerging GIS trends and network with innovators

Wave Life Sciences (WVE) is rated Hold, reflecting high pipeline potential but significant clinical, regulatory, and commercial risks. WVE-006 regaining global rights from GSK raises both opportunity and concern; upcoming RestorAATion-2 multidose data in 1Q26 is a key catalyst.